KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Total Current Liabilities (2016 - 2026)

Palvella Therapeutics has reported Total Current Liabilities over the past 10 years, most recently at $36.6 million for Q4 2022.

  • Quarterly Total Current Liabilities fell 27.65% to $36.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $36.6 million through Dec 2022, down 27.65% year-over-year, with the annual reading at $36.6 million for FY2022, 27.65% down from the prior year.
  • Total Current Liabilities was $36.6 million for Q4 2022 at Palvella Therapeutics, up from $33.5 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $54.8 million in Q1 2018 and troughed at $18.3 million in Q2 2020.
  • The 5-year median for Total Current Liabilities is $39.7 million (2019), against an average of $37.2 million.
  • Year-over-year, Total Current Liabilities surged 378.5% in 2018 and then plummeted 55.39% in 2020.
  • A 5-year view of Total Current Liabilities shows it stood at $48.1 million in 2018, then tumbled by 43.83% to $27.0 million in 2019, then dropped by 17.99% to $22.1 million in 2020, then skyrocketed by 128.32% to $50.6 million in 2021, then fell by 27.65% to $36.6 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Total Current Liabilities are $36.6 million (Q4 2022), $33.5 million (Q3 2022), and $35.5 million (Q2 2022).